Reviews the unique new pharmaceutical agent OraVerse (phentolamine mesylate) for reversal of soft tissue anesthesia. Covers duration of anesthesia following administration of OraVerse, administration protocols, adverse events, mechanisms of action, dosage protocols, costs of administration and clinical trials data. California Dental Board approved CE. AGD PACE National approved CE. Remote self-directed distance learning online dental CE course.